Text Size

Non-Interventional Study of Cough Variant Asthma Treatment With Pulmicort®Respules® in Children Outpatients (PUL NIS)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00660114
First received: April 15, 2008
Last updated: May 27, 2009
Last verified: May 2009
History of Changes
  Purpose

This open label, non-interventional study is to show the efficacy of Pulmicort®Respules® in cough variant asthma in patient aged 5-year old or younger in outpatient department


Condition
Cough Variant Asthma

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Non-Interventional Study of Cough Variant Asthma Treatment With Pulmicort®Respules® in Patient Aged 5-Year Old or Younger in Outpatient Department

Resource links provided by NLM:

MedlinePlus related topics: Asthma Cough
Drug Information available for: Budesonide
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Patient Symptom Score [ Time Frame: 7 weeks (plus or minus 3 days ) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Patient Compliance Report [ Time Frame: 7 weeks (plus or minus 3 days ) ] [ Designated as safety issue: No ]
  • Investigator Assessment Report [ Time Frame: 7 weeks (plus or minus 3 days ) ] [ Designated as safety issue: No ]

Enrollment: 914
Study Start Date: April 2008
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   up to 5 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patient aged 5-year old or younger who has been diagnosed as cough variant asthma and decided by physician to use Pulmicort® Respules® inhalation.

Criteria

Inclusion Criteria:

  • Provision of informed consent
  • Patient who has been prescribed Pulmicort® Respules® according to physician's judgement, irrespective of the inclusion in the study.
  • The usage of Pulmicort® Respules® follows local authorised package insert.

Exclusion Criteria:

  • Allergy to any ingredient of Pulmicort® Respules®
  • With history of Leukotriene Modifier (LM) usage prior to 2 weeks of recruitment or following plan.
  • Have used systemic/inhaled steroid prior to 2 weeks of recruitment
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00660114

  Show 32 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Hong Jianguo, Professor Shanghai Jiao Tong University Affiliated First People's Hospital,
  More Information

No publications provided

Responsible Party: Lars-Göran Carlsson - Medical Science Director, AstraZeneca
ClinicalTrials.gov Identifier: NCT00660114     History of Changes
Other Study ID Numbers: NIS-RCN-PUL-2008/1
Study First Received: April 15, 2008
Last Updated: May 27, 2009
Health Authority: China: Food and Drug Administration

Keywords provided by AstraZeneca:
Cough variant asthma
Pulmicort® Respules®
Chinese patient Eligibility

Additional relevant MeSH terms:
Asthma
Cough
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Respiration Disorders
Signs and Symptoms, Respiratory
Signs and Symptoms
 Budesonide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Anti-Inflammatory Agents

ClinicalTrials.gov processed this record on May 19, 2013